Surrey Heartlands

Joint Formulary & PAD

Palforzia (peanut protein) - Peanut allergy in children and young people

You are here : Home > Formulary Search > Palforzia (peanut protein) - Peanut allergy in children and young people

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NICE
Restrictions / Comments :
Important
Service not currently provided by Surrey Heartlands Trusts

Documentation

Evidence Review
Palforzia NICE TA769 briefing summary - April 2022 .pdf
Webpage
Palforzia - risk management materials
Webpage
NICE TA769 - Palforzia for treating peanut allergy in children and young people

PAD Profile

ChemicalSubstance :
Palforzia (peanut protein)
Indication :
Peanut allergy in children and young people
Group Name :
Keywords :
hyposensitising agents
Brand Names Include :
Palforzia
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Palforzia (peanut protein) is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Peanut allergy in children and young people.

  • No records returned.

Committee Recommendations (1)

04 May 22 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends Palforzia for treating peanut allergy in children and young people in line with NICE TA 769.

Palforzia will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA769.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication